세계의 감염증 치료제 시장 규모는 2022년에 1,168억 달러로 평가되었고, 2023년 1,217억 1,000만 달러에서 2031년에는 1,691억 4,000만 달러로 성장할 것으로 예상되며, 예측 기간 중(2024-2031년)의 CAGR은 4.2%로 성장할 전망입니다.
세계의 헬스케어 부문은 바이러스 및 박테리아를 포함한 다양한 병원체에 의해 유발되는 감염병으로 인한 엄청난 과제에 직면해 있습니다. 진단법, 치료법, 백신 접종 등의 예방책이 진보하고 사망률이 떨어졌음에도 불구하고 이들 질병의 재발은 여전히 공중보건상의 중대한 문제입니다. 그 결과, 감염률의 상승, 조기 진단에 대한 의식의 고조, 정부나 민간단체에 의한 연구 자금의 증가 등을 배경으로, 감염증 치료제 시장은 큰 성장을 이루고자 하고 있습니다. 그러나 선진적인 치료는 고가이기 때문에 많은 환자의 접근이 제한되어 시장 확대의 과제가 되고 있습니다. 게다가 저렴한 제네릭 의약품을 선호하는 경향이 강해지고 있어 감염병 대책을 목적으로 한 브랜드 치료제의 성장을 위협하고 있습니다.
Global Infectious Disease Therapeutics Market size was valued at USD 116.8 billion in 2022 and is poised to grow from USD 121.71 billion in 2023 to USD 169.14 billion by 2031, growing at a CAGR of 4.2% during the forecast period (2024-2031).
The global healthcare sector continues to face immense challenges due to infectious diseases, which are triggered by a range of pathogens including viruses and bacteria. Despite progress in diagnostics, treatment methods, and preventive measures like vaccinations that have lowered mortality rates, the resurgence of these diseases remains a critical public health issue. Consequently, the infectious disease therapeutics market is poised for considerable growth, driven by rising infection rates, heightened awareness for early diagnosis, and increased funding for research from governmental and private entities. Nonetheless, the expensive nature of advanced treatments poses a challenge for market expansion, limiting access for many patients. Additionally, the growing preference for affordable generic medications threatens the growth of branded therapeutics aimed at combating infectious diseases.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infectious Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Infectious Disease Therapeutics Market Segmental Analysis
Global Infectious Disease Therapeutics Market is segmented by type, treatment, end users and region. Based on type, the market is segmented into HIV, hepatitis, influenza, TB, malaria and HPV. Based on treatment, the market is segmented into antibacterial, antifungal drugs, antiviral drugs and others. Based on end users, the market is segmented into hospitals and clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Infectious Disease Therapeutics Market
The global infectious disease therapeutics market is likely to experience significant growth due to several driving factors. An increase in investment aimed at improving access to treatments for infectious diseases, along with strategic initiatives to raise awareness regarding both the treatments and diagnostics of these conditions, will contribute positively to market expansion. Furthermore, there has been a noticeable rise in clinical trial research dedicated to the development of innovative pharmaceutical solutions. Collectively, these elements are expected to propel the demand for infectious disease therapeutics, shaping a promising outlook for the market in the coming years.
Restraints in the Global Infectious Disease Therapeutics Market
The growth of the Global Infectious Disease Therapeutics market may be hindered by several factors, particularly the lack of awareness regarding available treatment options. In many developing nations, there is insufficient adoption of these therapies, compounded by limited reimbursement options for specific infectious diseases. This combination of inadequate understanding and accessibility can significantly restrain the market's expansion throughout the projected timeframe, as healthcare providers and patients may not fully utilize or access the innovative treatments necessary to combat these diseases effectively. Consequently, addressing these challenges is crucial for the market to reach its full potential in the coming years.
Market Trends of the Global Infectious Disease Therapeutics Market
The Global Infectious Disease Therapeutics market is witnessing significant growth, driven by the rising prevalence of malaria, particularly in developing regions such as India, Africa, and Southeast Asia. This surge is further fueled by increased research and development efforts from key pharmaceutical manufacturers and healthcare organizations aimed at advancing therapeutic options. Innovations in drug formulations and delivery methodologies, coupled with heightened awareness and funding for infectious disease management, are propelling the market forward. Additionally, strategic collaborations and partnerships in the healthcare sector are expected to enhance access to effective treatments, thereby shaping a robust market landscape in the coming years.